Summary
The authors studied the behavior of plasma levels of glucagon, HGH and insulin in a group of cirrhotic patients both in basal conditions and after i.v. arginine and glucose in order to assess their respective importance in the pathogenesis of carbohydrate disorders. After i.v. arginine an increased plasma concentration of pancreatic glucagon was found which reached its highest level at 15 min; i.e. glucose did not suppress the increased plasma glucagon levels. Plasma HGH which is consistently increased is not influenced by i.v. glucose. Plasma insulin was consistently raised during both tests; however, the insulinogenic index after i.v. glucose behaved like that of mild diabetics. The true importance of glucagon in the pathogenesis of carbohydrate intolerance in cirrhotics cannot as yet be determined with certainty; according to the authors, hyperglucagonemia is not the primary factor but only one of the main causes of this intolerance.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ansorge S., Kaiser B., Senger U., Bohley P., Langner J., Kirschke E. H.: Metabolismus von Insulin und Glukagon über die Heterogenität und zur Charakterisierung der Insulin und Glukagon abbauenden Enzymsysteme in Rattenleberzellfraktionen — Acta biol. med. Germ.28, 761, 1972.
Berkowitz D.: Glucose Tolerance, Free Fatty Acid, and Serum Insulin Responses in Patients with Cirrhosis — Amer. J. dig. Dis.14, 691, 1969.
Berson S. A., Yalow R. S., Volk B. W.: In Vivo and in Vitro Metabolism of Insulin-I131 and Glucagon-I131 in Normal and Cortisone-Treated Rabbits — J. Lab. clin. Med.49, 331, 1957.
Cerletty J. M., Engbring N. H.: Azotemia and Glucose Intolerance — Ann. intern. Med.66, 1097, 1967.
Chlouverakis G., Harris P.: Non Esterified Fatty Acids and Lipoprotein Lipase Activity in Patients with Cirrhosis of the Liver — Gut2, 233, 1961.
Collins J. R., Lacy W. W., Stiel J. N., Crofford O. B.: Glucose Intolerance and Insulin Resistance in Patients with Liver Disease. II. A Study of Etiologic Factors and Evaluation of Insulin Actions — Arch. intern. Med.126, 608, 1970.
Conn H. O.: Cirrhosis and Diabetes. IV. Effect of Potassium Chloride Administration on Glucose and Insulin Metabolism — Amer. J. med. Sci.259, 394, 1970.
Conn H. O., Daughaday W. H.: Cirrhosis and Diabetes. V. Serum Human Growth Hormone Levels in Laennec’s Cirrhosis — J. Lab. clin. Med.76, 678, 1970.
Conn H. O., Schreiber W., Elkington S. G.: Cirrhosis and Diabetes. II. Association of Impaired Glucose Tolerance with Portal-Systemic Shunting in Laennec’s Cirrhosis — Amer. J. dig. Dis.16, 227, 1971.
Creutzfeldt W., Frerichs H., Kraft W.: The Intravenous Tolbutamide Test in Liver Disease — In:Creutzfeldt W., Czyźyk A. (Eds): On the Intravenous Tolbutamide Test. Casa Ed. « Il Ponte », Milano, 1967; Acta diabet. lat.4 (Suppl. 1), 209, 1967.
Cruz A., David H., Thervet F., Rambert P., Benard H.: Le test au tolbutamide intraveineux au cours des atteintes hépatiques de l’alcoolisme chronique — Diabète (Le Raincy)17, 29, 1969.
De Moura M. C., Cruz A. G.: Carbohydrate Metabolism Studies in Cirrhosis of the Liver — Amer. J. dig. Dis.13, 891, 1968.
Dohan F. C., Richardson E. M., Bluemle L. W. Jr., György P.: Hormone Excretion in Liver Disease — J. clin. Invest.31, 481, 1952.
Felber J. P., Magnenat P., Vannotti A.: Tolérance au glucose diminuée et reponse insulinique élevés dans la cirrhose — Schweiz. med. Wschr.97, 1537, 1967.
Frantz A. G., Rabkin M. T.: Effects of Estrogen and Sex Differences on Secretion of Human Growth Hormone — J. clin. Endocr. 25, 1470, 1965.
Garcia J. F., Linfoot J. A., Manougian E., Born J. L., Lawrence J. H.: Plasma Growth Hormone Studies in Normal Individual and Acromegalic Patients — J. clin. Endocr.27, 1305, 1967.
Glick S. M., Roth J., Yalow R. S., Berson S. A.: Regulation of Growth Hormone Secretion — Recent Progr. Hormone Res.21, 241, 1965.
Herbert V., Lau K. S., Gottlieb C. W., Bleicher S. J.: Coated Charcoal Immunoassay of Insulin — J. clin. Endocr.25, 1375, 1965.
Hernandez A., Zorrilla E., Gershberg H.: Decreased Insulin Production, Elevated Growth Hormone Levels, and Glucose Intolerance in Liver Disease — J. Lab. clin. Med.73, 25, 1969.
Kaplan M.: Tolbutamide Tolerance Test in Carbohydrate Metabolism Evaluation — Arch. intern. Med.107, 212, 1961.
Kasperska T., Ławecki J., Rogala H., Czyźyk A.: The Behaviour of Insulinemia in Patients with Liver Cirrhosis after Intravenous Administration of Glucose, Tolbutamide and Glucagon — Diabetologia7, 391, 1971.
Marco J., Calle C., Roman D., Diaz-Fierros M., Villanueva M. L., Valverde I.: Hyperglucagonism Induced by Glucorticoid Treatment in Man — New Engl. J. Med.288, 128, 1973.
Marco J., Diego J., Villanueva M. L., Diaz-Fierros M., Valverde I., Segovia J. M.: Elevated Plasma Glucagon Levels in Cirrhosis of the Liver — New Engl. J. Med.289, 1107, 1973.
Marks P. A., Bishop J. S.: The Glucose Metabolism of Patients with Malignant Disease and of Normal Subjects as Studied by Means of an Intravenous Glucose Tolerance Test — J. clin. Invest.36, 254, 1957.
Megyesi C., Samols E., Marks V.: Glucose Tolerance and Diabetes in Chronic Liver Disease — Lancet2, 1051, 1967.
Patrono C., Fuhrman R., Yalow R. S.: Unpublished data.
Pimstone B., Barbezat G., Hausen J. D. L., Murray P.: Growth Hormone and Protein Caloric Malnutrition — Lancet2, 1333, 1967.
Rambert P., Thervet F.: Le test au tolbutamide intraveineux — Journées Annuelles de Diabétologie de l’Hôtel-Dieu, Paris 1968. Flammarion Éd., Paris, 1968; p. 331.
Rüedi B., Aubert M., Borel G. A., Magnenat P., Felber J. P.: Étude de la fonction Somatotrope du cirrhotique — Schweiz. med. Wschr.99, 1119, 1969.
Rupp J., Cantarow A., Rakoff A. E., Paschkis K. E.: Hormone Excretion in Liver Disease and in Gynecomastia — J. clin. Endocr.11, 688, 1951.
Sagild U., Andersen V., Andersen P. B.: Glucose Tolerance and Insulin Responsiveness in Experimental Potassium Depletion — Acta med. scand.169, 243, 1961.
Samaan N. A., Stone D. B., Eckhardt R. D.: Serum Glucose, Insulin and Growth Hormone in Chronic Hepatic Cirrhosis — Arch. intern. Med.124, 149, 1969.
Samols E., Marks V.: Nouvelles conceptions sur la signification fonctionnelle du glucagon (pancréatique et extrapancréatique) — Journées Annuelles de Diabétologie de l’Hôtel-Dieu, Paris 1967. Flammarion Éd., Paris, 1967; p. 43.
Schalch D. S., Parker M. L.: A Sensitive Double Antibody Immunoassay for Human Growth Hormone in Plasma — Nature (Lond.)203, 1141, 1964.
Schwartz E., Echemendia E., Schiffer M.: Peripheral Metabolic Antagonism of Estrogen and Human Growth Hormone — J. clin. Invest.46, 1115, 1967.
Seltzer H. S., Allen E. W., Herron A. L. Jr., Brennam M. T.: Insulin Secretion in Response to Glycemic Stimulus: Relation of Delayed Initial Release to Carbohydrate Intolerance in Mild Diabetes Mellitus — J. clin. Invest.46, 323, 1967.
Sherwin R., Joshi P., Hendler R., Felig P., Conn H. O.: Hyperglucagonemia in Laennec’s Cirrhosis: Role of Portal-Systemic Shunting — New Engl. J. Med.290, 239, 1974.
Stocks A. E., Powell L. W.: Pituitary Function in Idiopathic Haemochromatosis and Cirrhosis of the Liver — Lancet2, 298, 1972.
Sullivan J. F., Swartz M. J., Robertson P. R.: Hyperlipemia in Laennec’s Cirrhosis — Amer. J. med. Sci.246, 451, 1963.
Tchobroutsky G., Collin de L’HortetG., Rosselin G., Assan R., Dérot M.: Étude de la glycorégulation dans l’insuffisance rénale chronique. I. — Diabetologia1, 101, 1965.
Tiengo A., Muggeo M., Fedele D., Enzi G., Fellin R., Grepaldi G.: Il comportamento dell’insulinemia dopo carico orale di glucosio e glucagone e.v. in pazienti con cirrosi epatica, con cirrosi e diabete e con anastomosi porto-cava — Fegato15, 265, 1969.
Unger R. H.: New Ideas Concerning the Physiologic Roles of Glucagon — Amer. J. med. Sci.255, 273, 1968.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Greco, A.V., Ghirlanda, G., Patrono, C. et al. Behavior of pancreatic glucagon, insulin, and HGH in liver cirrhosis, after arginine and i.v. glucose. Acta diabet. lat 11, 330–339 (1974). https://doi.org/10.1007/BF02581236
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02581236